Navigation Links
Scott & White Healthcare researcher finds success with new anti-cancer drug
Date:12/22/2009

A study conducted at Scott & White Healthcare in Temple, Texas, found that a new drug stopped the growth of breast tumors in mice. This drug is unique in that it works both by stopping the cancer cells from growing and metastasizing to other organs, and by stimulating the immune system to destroy breast cancer cells and keeps them from coming back. This is the only drug that's able to work in both ways, while all other treatments work in one way or another. And, this research initiative not only involves physicians and biologists working together to bring treatments from the laboratory to the bedside, but a unique third component agriculturalists.

Researcher Alexzander Asea, Ph.D., the Effie and Wofford Cain Endowed Chair in Clinical Pathology, and division chief of investigative pathology at Scott & White Healthcare and the Texas A&M Health Science Center, said "we found that some of the mice were essentially cured."

"All anti-cancer drugs broadly fall into two categories; either directly killing cancer cells (often healthy cells as well), or vaccines that help sick patients by boosting the immune system to better fight off cancer. This new drug works both ways, as a vaccine by taking away the cancer cell ability to grow, multiply and spread to distant organs, and by educating the immune system to recognize the breast cancer cells as 'foreign invaders' that need to be attacked and destroyed and to continue that process over time," Dr. Asea said.

Dr. Asea went on to say "breast cancer cells fly under the radar of the immune system, by turning off the machinery that normally puts recognition structures on the surface of cancer cells which the immune system uses to recognize and destroy them. To overcome this problem, this injectable drug turns on this machinery within the cancer cells allowing the immune system to recognize the cancer cells and kill them. The unique thing is that the revved-up immune cells will continue patrolling for any hidden cancer cells months and years after the last cancer cells have been killed," Dr. Asea said.

"Collaborating with the agricultural community on this research also allows us to use a special delivery mechanism of the drug that doesn't cause the negative side effects you see with more traditional treatments like chemotherapeutic agents," explained Dr. Asea.

Dr. Asea said only about one year of additional work is required before Phase I clinical trials can begin in women with metastatic breast cancer at Scott & White Hospital. "However, this stage requires a significant amount of funding. We're currently looking at various sources including federal, state and private sources to get this promising drug to the patients who need it."


'/>"/>

Contact: Katherine Voss
kvoss@swmail.sw.org
254-724-4097
Scott & White Healthcare
Source:Eurekalert

Related biology news :

1. Wolf reintroduction proposed in Scottish Highland test case
2. TGen Clinical Research Services at Scottsdale Healthcare and Mayo Clinic study new cancer drug
3. Phoenix conference highlights TGens and Scottsdale Healthcares contributions to molecular oncology
4. TGen, Scottsdale Healthcare, Mayo Clinic study new drug to stimulate immune system of cancer victims
5. American Society for Microbiology honors D. Scott Merrell
6. JDRF announces diabetes research program with Johnson & Johnson
7. Increased Spending on the EUs External Borders to Drive the Border Security Market, Says Frost & Sullivan
8. Frost & Sullivan Recognises Sagem Securite for its Innovative Automated Border Control Systems
9. Johnson & Johnson award goes to research of the cause of brain cell damage in Parkinsons
10. Texas A&M Researchers Examine How Viruses Destroy Bacteria
11. Innovative R&D prioritization tool earns Baxter the 2009 INFORMS Decision Analysis Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/29/2019)... ... 29, 2019 , ... Fujirebio Diagnostics, Inc., a consolidated subsidiary ... of the company’s Lumipulse® G whole PTH Assay for testing on its LUMIPULSE® ... parathyroid glands; which are four small glands located behind the thyroid gland. The ...
(Date:10/26/2019)... FRANCISCO (PRWEB) , ... October 23, 2019 , ... ... Operating Officer, Christina Hughes , to its executive leadership team. , As ... integrated technology solutions allow growth-stage biotech and pharma companies to reduce timelines and ...
(Date:10/26/2019)... ... October 24, 2019 , ... THE PRINCESS VEST, Made ... the standard choice for female providers, they were the only choice. Women in radiology ... or a loose garment that can allow harmful radiation to penetrate the sides of ...
Breaking Biology News(10 mins):
(Date:10/26/2019)... ... October 24, 2019 , ... ... Bichsel Medical Marketing Group (BMMG), a boutique healthcare-specific marketing firm, to strengthen ... its in-house Healthcare Strategy Division. , Healthcare clients in pharma, bio-therapeutics, medical device ...
(Date:10/22/2019)... ... October 22, 2019 , ... DermBiont, ... its lead program, DBI-001, met its primary safety endpoints, with no application site ... clinical trial for the treatment of interdigital tinea pedis (athlete’s foot). Additionally, the ...
(Date:10/10/2019)... NORTH BETHESDA, Md. (PRWEB) , ... October 09, ... ... (ISPE) announced Amy Abernethy, MD, PhD, Principal Deputy Commissioner, FDA, as a ... taking place 27–30 October 2019 in Las Vegas, Nevada USA. , Dr. Abernethy, ...
(Date:10/8/2019)... Calif. (PRWEB) , ... October 08, 2019 , ... ... Master’s Project (TMP), Madhumita Suresh and Leslie Maurer presented company executives with a ... Business and Science (MBS) graduates will offer insights from their TMP to a ...
Breaking Biology Technology: